Introduction: Microvascular and endothelial disorders play a significant role in the pathophysiology of coronary slow flow phenomenon (CSFP). However, according to previous studies, etiology CSFP is not completely understood. As CD40 dipeptidyl peptidase-4 (DPP-4) are reported an important atherosclerosis process as well microvascular dysfunction, this study evaluated these two biomarkers CSFP....

Objective: This study was aimed at investigating the effects of preoperative treatment with a loading dose statins combined PCSK9 inhibitor on coronary blood perfusion and short-term cardiovascular adverse events in patients ST-segment elevation myocardial infarction (STEMI). Method: Sixty-five STEMI who had visited Shanxi Cardiovascular Disease Hospital between May 2018 2021 were enrolled stud...

The underlying mechanisms behind the effect of atorvastatin on patients with coronary slow flow (CSF) remain largely unknown. To investigate the possible underlying molecular mechanisms 108 patients were divided into atorvastatin group and control group. Coronary flow was quantified according to corrected TIMI frame count (CTFC). Serum high sensitivity C-reactive protein (hs-CRP), lipids, ET-1,...

  Introduction: No-reflow phenomenon in coronary vessels, manifested in some patients with reperfused acute myocardial infarction (MI), is associated with poor clinical and functional outcomes. Therefore, evaluation of predisposing risk factors can be helpful in risk assessment and identification of patients at higher risk. Herein, we aimed to study the predictive factors for the development of...

Since the introduction of reperfusion therapy in the early 1980s, cardiologists have largely focused on coronary artery flow and diameter, with the goal being to restore normal epicardial artery perfusion and large lumens. For many years, epicardial coronary flow has been simply assessed by the TIMI (thrombolysis in myocardial infarction) flow grade. This semiquantitative coronary angiographic ...